- Home
- Publications
- Publication Search
- Publication Details
Title
Cardiovascular toxicity of anti-angiogenic drugs
Authors
Keywords
-
Journal
Targeted Oncology
Volume 6, Issue 4, Pages 197-202
Publisher
Springer Nature
Online
2011-11-24
DOI
10.1007/s11523-011-0204-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Takotsubo cardiomyopathy in two men receiving bevacizumab for metastatic cancer
- (2016) Therese Franco Therapeutics and Clinical Risk Management
- Effects of Novel Angiogenesis Inhibitors for the Treatment of Cancer on the Cardiovascular System
- (2011) Babak Nazer et al. CIRCULATION
- Risk of high-grade bleeding in patients with cancer treated with bevacizumab: a meta-analysis of randomized controlled trials
- (2011) Xiao Feng Hang et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Treatment-Related Mortality With Bevacizumab in Cancer Patients
- (2011) Vishal Ranpura et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Venous Thromboembolic Events With Chemotherapy Plus Bevacizumab: A Pooled Analysis of Patients in Randomized Phase II and III Studies
- (2011) Herbert I. Hurwitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Congestive Heart Failure Risk in Patients With Breast Cancer Treated With Bevacizumab
- (2011) Toni K. Choueiri et al. JOURNAL OF CLINICAL ONCOLOGY
- Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis of randomized controlled trials
- (2010) Vishal Ranpura et al. ACTA ONCOLOGICA
- Risk/benefit profile of bevacizumab in metastatic colon cancer: A systematic review and meta-analysis
- (2010) Elena Galfrascoli et al. DIGESTIVE AND LIVER DISEASE
- Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: an updated meta-analysis
- (2010) Mao Mao An et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Initial Assessment, Surveillance, and Management of Blood Pressure in Patients Receiving Vascular Endothelial Growth Factor Signaling Pathway Inhibitors
- (2010) Michael L. Maitland et al. JNCI-Journal of the National Cancer Institute
- Increased Risk of Serious Hemorrhage with Bevacizumab in Cancer Patients: A Meta-Analysis
- (2010) Sanjaykumar Hapani et al. ONCOLOGY
- Biology of Anti-Angiogenic Therapy–Induced Thrombotic Microangiopathy
- (2010) Vera Eremina et al. SEMINARS IN NEPHROLOGY
- Antiangiogenic Drugs in Oncology: A Focus on Drug Safety and the Elderly – A Mini-Review
- (2009) S. Boehm et al. GERONTOLOGY
- Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: Systematic review and meta-analysis
- (2008) Xiaolei Zhu et al. ACTA ONCOLOGICA
- Risk of Venous Thromboembolism With the Angiogenesis Inhibitor Bevacizumab in Cancer Patients
- (2008) Shobha Rani Nalluri et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Cardiac Toxicity of Sunitinib and Sorafenib in Patients With Metastatic Renal Cell Carcinoma
- (2008) Manuela Schmidinger et al. JOURNAL OF CLINICAL ONCOLOGY
- A Randomized, Double-Blind, Phase IIa Dose-Finding Study of Vandetanib (ZD6474) in Japanese Patients With Non-Small Cell Lung Cancer
- (2008) Katsuyuki Kiura et al. Journal of Thoracic Oncology
- Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis
- (2008) Shenhong Wu et al. LANCET ONCOLOGY
- VEGF Inhibition and Renal Thrombotic Microangiopathy
- (2008) Vera Eremina et al. NEW ENGLAND JOURNAL OF MEDICINE
- Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation
- (2007) J.-J. Mourad et al. ANNALS OF ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now